Short-term treatment of iron deficiency anemia after cardiac surgery

Venturini, Elio; IANNUZZO, Gabriella; LORENZO, Anna DI; CUOMO, Gianluigi; D'ANGELO, Andrea; MERONE, Pasquale; CUDEMO, Giuseppe; Pacileo, Mario; D’Andrea, Antonello; VIGORITO, Carlo; Giallauria, Francesco

doi:10.1016/j.ijcha.2022.101038

Cited by 5 publications

(4 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned erlier, Sucrosomial® iron absorption is mostly hepcidin-independent, as it is taken up to the lymphatic circulation through transcellular and M cell-mediated endocytosis routes [ 9 ]. This gives Sucrosomial® iron the ability to increase Hb levels, even in the presence of inflammation, as demonstrated in cardiac surgery [ 25 , 26 ] and in patients with chronic kidney disease [ 27 ], cancer [ 28 ] or inflammatory bowel disease [ 29 , 30 ]. Notably, the efficacy of Sucrosomial® iron is observed at much lower dose and with fewer gastrointestinal adverse events compared to oral iron sulfate.…”

Section: Discussionmentioning

confidence: 99%

Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period

Edu

Mehedințu

Mitran

et al. 2023

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

Background Postpartum iron deficiency anemia (PPIDA) is highly prevalent in developing countries where it constitutes an important cause of maternal morbidity and mortality. Potential determinants of PPIDA are prepartum iron deficiency or iron deficiency anemia in association with severe blood loss during delivery. We investigated the efficacy of oral Sucrosomial® iron for recover from mild-to-moderate PPIDA. Methods This pilot study was conducted in three medical centers in Romania. Adult women (≥ 18y) with mild (hemoglobin [Hb] 9–11 g/dL) or moderate (Hb 7–9 g/dL) PPIDA diagnosed at screening (2–24 h after delivery) were eligible. Women with mild PPIDA received oral Sucrosomial® iron (Pharmanutra, S.p.A, Italy) once daily (30 mg elemental iron per capsule) for 60 days. Those with moderate PPIDA received oral Sucrosomial® iron twice daily (60 mg elemental iron) for 10 days, followed by a 50-day course of oral Sucrosomial® iron once daily (30 mg elemental iron). Laboratory parameters, as well as subjective clinical symptoms using a 3-point Likert Scale, were assessed at baseline and on study days 10, 30 and 60. Results Sixty anemic women entered the study, but three were missed during follow-up. At day 60, a Hb rise was observed in both groups (+ 3.6 ± 1.5 g/dL; p < 0.01), 81% experienced correction of anemia (Hb ≥ 12 g/dL), 36% achieved a ferritin concentration ≥ 30 ng/mL (p < 0.05), and 54% a transferrin saturation (TSAT) ≥ 20% (p < 0.01). For women still anemic at day 60, mean Hb was close to normality (11.3 ± 0.8 g/dL). Resolution of IDA-associated clinical symptoms was already observed just 10 days after treatment initiation. No patient discontinued treatment due to gastrointestinal adverse events. Conclusions Sucrosomial® iron was shown to be potentially effective and well tolerated at treating mild and moderate PPIDA. These results encourage the use of oral Sucrosomial® iron as a treatment option for PPIDA, but larger studies with longer follow-up are warrant.

show abstract

Section: Discussionmentioning

confidence: 99%

Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period

Edu

Mehedințu

Mitran

et al. 2023

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

show abstract

“…Only two studies in the literature examined these two factors' baseline values during iv ferric carboxymaltose treatment, and just one of them included first month follow-up values. Venturini et al [26] analyzed 106 patients with IDA on admission to a cardiac rehabilitation unit after cardiac surgery. They treated patients with iv ferric carboxymaltose or oral sucrosomial iron.…”

Section: Discussionmentioning

confidence: 99%

Ferric Carboxymaltose Versus Ferrous Glycine Sulfate For Treatment of Iron Deficiency Anemia and Their Effect On Vitamin B12 And Folic Acid: A Retrospective Study

Erdem

2022

Archives of Clinical and Experimental Medicine

View full text Add to dashboard Cite

Aim Anemia is a major public health problem, affecting about one-third of the world's population, and is most commonly caused by iron deficiency. Iron deficiency anemia requires oral or intravenous iron replacement therapy. The purpose of this study was to assess the change in several hematological parameters, vitamin B12, and folic acid from baseline to the first month of follow-up following therapy with oral ferrous glycine sulfate or intravenous ferric carboxymaltose. Methods: All patients who received oral ferrous glycine sulfate or intravenous ferric carboxymaltose for the treatment of iron deficiency anemia between January 1, 2016, and December 31, 2018, were included in the trial. Along with age and gender information, values of hemoglobin, ferritin, transferrin saturation, mean corpuscular volume, vitamin B12, and folic acid were derived from patients’ records at the beginning of treatment and first month follow-up. Results: Laboratory values obtained after treatment showed statistically significant improvement in both groups (intra group, p<0.001). When the percentage of change between groups was compared: Percentage-based increases in hemoglobin, mean corpuscular volume, transferrin saturation and ferritin values were significantly higher in the ferric carboxymaltose group (p<0.001). The percentage decrease in vitamin B12 and folic acid values was higher in the ferric carboxymaltose group (p=0.005 and p=0.01, respectively) when compared with oral ferrous glycine sulfate group. Conclusions: According to the findings of our study, iron deficiency anemia can be treated very successfully using ferric carboxymaltose; however, it should be remembered that concurrent supplementation of elements such vitamin B12 and folic acid is necessary for the appropriate progression of erythropoiesis.

show abstract

“…As for post-operative anemia, 106 consecutive patients presenting with IDA on post-operative day (POD) 10 after CS (T1) were treated with SI ( n = 54) or FCM n = 52) [ 134 ]. Patients received a single dose of FCM (1000 mg) on POD 10 or oral SI (120 mg/day from POD10 to POD20 plus 30 mg/day from POD21 to POD30).…”

Section: Sucrosomial ® Iron For the Management Of ...mentioning

confidence: 99%

“…Over time, CRP levels decreased ( p < 0.001), while 6MWT values improved ( p < 0.001), without significant differences between groups ( p = 0468). Brain natriuretic peptide concentrations were reduced during the follow-up, with both treatments, but not significantly [ 134 ] ( Table 4 ).A similar improvement in post-operative Hb recovery was registered in a small RCT of 51 patients undergoing abdominal aortic aneurism repair comparing SI (30 mg/day for 30 days) versus no treatment (Hb increment: 1.9 g/dL vs. 0.4 g/dL, respectively) [ 135 ] ( Table 4 ).…”

Section: Sucrosomial ® Iron For the Management Of ...mentioning

confidence: 99%

Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency

Gómez‐Ramírez

Brilli²,

Tarantino³

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Iron deficiency (ID) and iron deficiency anemia (IDA) are highly prevalent worldwide. Oral iron salts, especially ferrous sulfate, are commonly used for the treatment of iron deficiency (ID). However, its use is associated with gastrointestinal side effects, thus compromising treatment compliance. Intravenous iron administration is a more costly and logistically complex alternative and is not risk-free, as infusion and hypersensitivity reactions may occur. Sucrosomial® iron is an oral formulation consisting of ferric pyrophosphate conveyed by a phospholipid and sucrester matrix (sucrosome®). Intestinal Sucrosomial® iron absorption is mediated by enterocytes and M cells, through the paracellular and transcellular routes, and occurs mostly as intact particles. These pharmacokinetic properties of Sucrosomial® iron result in higher iron intestinal absorption and excellent gastrointestinal tolerance compared to oral iron salts. The evidence derived from clinical studies supports the use of Sucrosomial® iron as a valid first option for the treatment of ID and IDA, especially for subjects who are intolerant or refractory to conventional iron salts. Newer evidence also demonstrates the effectiveness of Sucrosomial® iron, with a lower cost and fewer side effects, in certain conditions usually treated with IV iron in current clinical practice.

show abstract

Short-term treatment of iron deficiency anemia after cardiac surgery

Cited by 5 publications

References 64 publications

Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period

Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period

Ferric Carboxymaltose Versus Ferrous Glycine Sulfate For Treatment of Iron Deficiency Anemia and Their Effect On Vitamin B12 And Folic Acid: A Retrospective Study

Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency

Contact Info

Product

Resources

About